NDA 021265 · Sandoz Canada INC
Infuvite Pediatric (Pharmacy Bulk Package)
Ascorbic Acid, Biotin, Cholecalciferol, Cyanocobalamin, Dexpanthenol, Folic Acid, Niacinamide, Pyridoxine, Riboflavin, Thiamine, Tocopherol Acetate, Vitamin A, Vitamin K · Intravenous
Last checked: Nov 20, 2026Latest source record: Nov 6, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Feb 21, 2001
Approved uses
1
Original approval plus efficacy supplements
Registered trials
617
128 Phase 3, 49 recruiting
FAERS reports
24
14 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 20, 2024.
INFUVITE PEDIATRIC is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition. The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. INFUVITE PEDIATRIC is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition ( 1 )
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE) · ASCORBIC ACID 80MG/VIAL; BIOTIN 0.02MG/VIAL; CHOLECALCIFEROL 400 IU/VIAL; CYANOCOBALAMIN 0.001MG/VIAL; DEXPANTHENOL 5MG/VIAL; FOLIC ACID 0.14MG/VIAL; NIACINAMIDE 17MG/VIAL; PYRIDOXINE 1MG/VIAL; RIBOFLAVIN 1.4MG/VIAL; THIAMINE 1.2MG/VIAL; TOCOPHEROL ACETATE 7 IU/VIAL; VITAMIN A 2,300 IU/VIAL; VITAMIN K 0.2MG/VIAL · INJECTABLE, INTRAVENOUS · Prescription · TE AP
- INFUVITE PEDIATRIC · ASCORBIC ACID 80MG/VIAL; BIOTIN 0.02MG/VIAL; CHOLECALCIFEROL 400 IU/VIAL; CYANOCOBALAMIN 0.001MG/VIAL; DEXPANTHENOL 5MG/VIAL; FOLIC ACID 0.14MG/VIAL; NIACINAMIDE 17MG/VIAL; PYRIDOXINE 1MG/VIAL; RIBOFLAVIN 1.4MG/VIAL; THIAMINE 1.2MG/VIAL; TOCOPHEROL ACETATE 7 IU/VIAL; VITAMIN A 2,300 IU/VIAL; VITAMIN K 0.2MG/VIAL · INJECTABLE, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Ascorbic Acid" as an intervention, any sponsor and status, largest first.
- Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)Pivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT04353180 · 100,000 participants (planned) · Start Aug 2021 · Primary completion Oct 2021
Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment; Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment and 3 more · For: COVID19
Sites: Cairo, Egypt · 2 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)Pivotal-lookingCompleted
The George Washington University Biostatistics CenterAcademic, hospital or other
NCT00135707 · 10,154 participants · Start Jun 2003 · Primary completion Oct 2008
Drug: Dietary Supplement/Vitamins; Placebo for Vitamin C and Vitamin E · For: Preeclampsia
Sites: Birmingham, Alabama; Chicago, Illinois; Detroit, Michigan · 16 sites in all
- A Preventive Treatment for Migrant Workers at High-risk of COVID-19Pivotal-lookingCompleted
National University Hospital, SingaporeAcademic, hospital or other
NCT04446104 · 4,257 participants · Start May 13, 2020 · Primary completion Aug 31, 2020
Drug: Hydroxychloroquine Sulfate Tablets; Ivermectin 3mg Tab and 2 more · For: Covid-19
Sites: Singapore, Singapore
- Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)Pivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00064753 · 4,110 participants · Start May 2002 · Primary completion Oct 2011
Drug: High Dose Multivitamin · For: Chronic Kidney Disease; Cardiovascular Disease; Death
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 30 sites in all
- A Randomized Multi-Intervention Trial to Inhibit Precancerous Gastric Lesions in Lingu, Shandong ProvincePivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00339768 · 3,411 participants · Start Jul 1, 1995 · Primary completion Jun 10, 1996
Drug: Amoxicillin/omeprazole · For: Precancerous Gastric Lesions
Sites: Beijing, China
- Perioperative Vitamin C to Reduce Persistent Pain After Total Knee ArthroplastyPivotal-lookingRecruiting
University Health Network, TorontoAcademic, hospital or other
NCT06123715 · 3,216 participants (planned) · Start Apr 16, 2024 · Primary completion Dec 31, 2029
Drug: Vitamin C; Placebo · For: Chronic Pain; Knee Pain Chronic; Post Operative Pain and 1 more
Sites: Toronto, Canada · 3 sites in all
- A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Mild Type of Hand, Foot, and Mouth DiseasePivotal-lookingCompleted
The First Affiliated Hospital of Anhui University of Traditional Chinese MedicineAcademic, hospital or other
NCT01182532 · 3,000 participants · Start May 2010 · Primary completion Oct 2011
Drug: TCM Syndrome Differentiation and Treatment · For: Hand, Foot and Mouth Disease
Sites: Hefei, China; Beijing, China; Chongqing, China · 21 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea4
- cough3
- erythema3
- rash generalised3
- tachycardia3
- vomiting3
- anaphylactic reaction2
- chest discomfort2
- grunting2
- hypersensitivity2
- medication error2
- paraesthesia2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 1 |
| 2016 | 5 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Recalls
1 FDA enforcement reports for this application.
Apr 21, 2020 · Class II · Terminated
Defective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple Vitamins
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Microneedling as an adjuvant to topical therapies for melasma: A systematic review and meta-analysis.
Bailey AJM, Li HO, Tan MG, et al. · J Am Acad Dermatol 2022 · Meta-Analysis, Systematic Review
- Vitamin C for preventing and treating the common cold.
Hemilä H, Chalker E · Cochrane Database Syst Rev 2013 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Randomized trial of topical ascorbic acid in DMSO versus imiquimod for the treatment of basal cell carcinoma.
Burke B, Bailie JE · Biomed Pharmacother 2022 · Randomized Controlled Trial
- Efficacy of vitamin C supplementation in preventing and treating complex regional pain syndrome type I (CRPS-I) in Orthopedic patients: A systematic review and meta-analysis.
Ranjbar Moghaddam M, Nasiri-Formi E, Merajikhah A · Int J Orthop Trauma Nurs 2024 · Systematic Review, Meta-Analysis
- Evaluation and clinical comparison studies on liposomal and non-liposomal ascorbic acid (vitamin C) and their enhanced bioavailability.
Gopi S, Balakrishnan P · J Liposome Res 2021 · Randomized Controlled Trial
- A randomized trial of ascorbic acid for the prevention of post-reperfusion syndrome during liver transplantation.
Gajate Martín L, de la Hoz I, Martín M, et al. · Hepatol Commun 2025 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Novartis · Also marketed as Infuvite Pediatric
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.